
Stimulating insulin secretion from the pancreas when blood glucose rises
Inhibiting glucagon release, which helps prevent excess glucose production by the liver
Slowing gastric emptying, leading to prolonged digestion and steadier blood sugar levels

Available as Victoza (for diabetes) and Saxenda (for weight management)
Available as Ozempic (for diabetes) and Wegovy (for weight management)
Available as Mounjaro (for diabetes and weight management)
GLP-1 agonists support type 2 diabetes management by increasing insulin secretion in response to elevated blood sugar and by reducing the liver’s release of glucose, resulting in better glycemic control. They are commonly added to treatment regimens when oral medications like metformin alone do not provide adequate control. Some GLP-1 agents have also been shown to protect cardiovascular health by lowering the risk of heart related events in patients with type 2 diabetes who already have heart disease.
For adults without diabetes, GLP-1 agonists including Wegovy and Saxenda have been granted FDA approval for chronic weight management. These drugs help patients feel fuller and less hungry, lowering calorie intake and making long term adherence to dietary changes more realistic. Clinical trial data demonstrate that GLP-1 therapy, when combined with lifestyle modifications, can produce substantial and durable weight loss.
GLP-1 receptor agonists help keep blood sugar in check by encouraging the pancreas to release insulin after meals and by decreasing glucagon production so less glucose is released from the liver. This combination limits sudden increases in blood glucose and promotes more controlled glycemic patterns. Because their activity is tied to current glucose levels, the risk of hypoglycemia is significantly lower than with many conventional diabetes drugs.
GLP-1 therapy is particularly effective for people seeking long lasting weight loss and better weight stability over time. By slowing gastric emptying and sending clear fullness signals to the brain, these medications ease hunger and support a natural decrease in how many calories are consumed. Clinical trials show that drugs such as liraglutide, semaglutide, and tirzepatide can achieve significant and sustained weight loss outcomes when integrated with lifestyle change programs.



GLP-1/GIP co-agonists work by activating both GLP-1 and GIP receptors, improving insulin release and appetite regulation more effectively than GLP-1 alone. These dual-action drugs provide a more potent solution for blood sugar control and hunger management, offering a promising treatment for obesity and diabetes.
GLP-1/glucagon co-agonists target both GLP-1 and glucagon receptors to improve weight loss and energy metabolism while helping to preserve lean muscle mass, supporting a healthier metabolic system.

